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The serum- and glucocorticoid-regulated kinase 1 (SGK1) is a serine-threonine kinase which
is emerging as an essential and non-redundant target in medicinal chemistry. SGK1 has 
demonstrated to be involved in cancer development and resistance, and in the metabolic 
syndrome, a pathological state mainly characterized by hypertension and obesity [1, 2]. Only 
few SGK1 inhibitors have been reported in the literature to date. 
Our research group synthesized a wide library of 4-amino-substituted pyrazolo[3,4-
d]pyrimidines active as dual Src/Abl inhibitors, two tyrosine kinases which are involved in 
many malignancies. Recently, we decided to virtually screen our in house library against 
SGK1 to evaluate the activity towards this emerging target. The most promising in silico
compounds have been tested in vitro and, among these, SI113 (Figure) showed an IC50 value 
of 600 nM on SGK1 and resulted selective for this kinase compared with AKT-1, Src and Abl. 
Furthermore, SI113 resulted active in vitro as antiproliferative agent on different cancer cell 
lines and also in glioblastoma and hepatocarcinoma xenograft mouse models [3,4]. For this 
reason we synthesized a new generation of SI113 derivatives, with the aim to find molecules 
with a higher activity and a better pharmacokinetic profile. We explored the effects of 
substitutions on N1 phenyl ring, and on C4 and C6 positions. In particular, we inserted polar 
groups such as the ethanolamino and diethanolamino moieties in C6 to improve the solubility 
of such molecules.
Synthesis and biological results will be reported in the poster section.
Figure: the SGK1 inhibitor SI113 
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